You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Overall outcomes from treatment with 2-year event rates showing differences between SUV max categories

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

    SUVmax < 5 SUVmax ≥ 5  
  2-year freedom from event (%) Total events n (%) 2-year freedom (%) 2-year freedom (%) K-M p
Local failure 93.7 8 (8.4) 97 86 .256
Regional failure 90.5 10 (10.5) 94 82 .131
Distant failure 86.3 15 (15.8) 91 78 .371
Any progression 93.7 25 (26.3) 88 62 .024
Death 64.2 48 (50.5) 72 49 .024
  1. Comparison of SUVmax categories shows a statistically significant difference in progression-free and overall survivals.